G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab

Autoři	FIALA Ondrej BUCHLER Tomas MOHELNIKOVA-DUCHONOVA Beatrice MELICHAR Bohuslav MATEJKA Vit Martin HOLUBEC Lubos KULHANKOVA Jana BORTLÍČEK Zbyněk BARTOUSKOVA Marie LISKA Vaclav TOPOLCAN Ondrej SEDIVCOVA Monika FINEK Jindrich
Rok publikování	2016
Druh	Článek v odborném periodiku
Časopis / Zdroj	Tumor Biology
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Doi	http://dx.doi.org/10.1007/s13277-015-4523-7
Obor	Onkologie a hematologie
Klíčová slova	Colorectal cancer; Bevacizumab; Chemotherapy; KRAS; Mutation
Popis	The v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are found in 35-45 % of colorectal cancer (CRC) cases, Although the association between the RAS signaling and angiogenesis is well known, the negative predictive value of KRAS mutation has not been established in patients treated with bevacizumab. The aim of this study was to evaluate the association between specific KRAS mutation types and outcome of patients with metastatic CRC treated with bevacizumab. The study included 404 patients with metastatic CRC (mCRC) treated with bevacizumab. Clinical data obtained from the clinical registry CORECT were retrospectively analyzed. The shortest survival was observed in patients with tumors harboring G12V or G12A KRAS mutation (G12V/A). The median progression-free survival (PFS) and overall survival (OS) for patients with tumors harboring G12V/A KRAS mutation was 6.6 and 16.8 compared to 11.6 and 26.3 months for patients with tumors harboring other KRAS mutation type (p<0.001 and p<0.001), while the survival of patients harboring other KRAS mutation types was comparable to those with tumors harboring wild-type KRAS gene. In the Cox multivariable analysis, KRAS G12V/A mutation type remains a significant factor predicting both PFS (HR=2.18,p<0.001) and OS (HR=2.58,p<0.001). In conclusion, the results of the present study indicate that there is a significant difference in biological behavior between tumors harboring G12V/A and other KRAS mutations. Moreover, comparison of the survival of patients with tumors harboring G12V/A KRAS mutations with those harboring wild type KRAS gene revealed that G12V/A KRAS mutations are prognostic biomarker for inferior PFS and OS in patients with mCRC treated with bevacizumab in univariate as well as multivariable analyses.